Cambridge-based digital health company CamDiab has introduced CamAPS Liberty, the world’s first commercially available fully closed-loop insulin delivery feature, at the Advanced Technologies & Treatments for Diabetes (ATTD) Congress 2026. The feature will be integrated into the existing CamAPS FX app used with compatible insulin pump systems.

Designed for people living with type 1 Diabetes, CamAPS Liberty allows users to temporarily step away from carbohydrate counting and pre-meal insulin boluses. When activated, an enhanced version of the system’s algorithm automatically anticipates and manages glucose fluctuations within defined safety limits.

Users still retain access to existing controls, including Boost, Ease-off, Add Meal, and manual boluses, while glucose data continues to be shared with care teams. Professor Roman Hovorka, founder of CamDiab, described the launch as “the dawn of commercially available fully closed-loop technology” and called it a major milestone for the diabetes community.

The feature received notified body approval in January 2026 and is being rolled out to mylife Loop AID and Dana pump users running CamAPS FX, pending market-specific approvals. The feature has not been tested for pregnancy or for children under 13, so it is not currently recommended for either yet.

The launch puts CamDiab ahead of competitors such as Insulet, maker of the Omnipod, whose own fully closed-loop system remains in earlier development, and that is for people with type 2 diabetes. For now, CamAPS Liberty stands alone as the first commercially available fully closed-loop option for people with type 1 diabetes. Meanwhile, many users of open source apps like Trio don’t bolus or log carbs.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.